Febuxostat National Contract
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-22-D-0142
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The "Febuxostat National Contract" (Procurement Identifier: SPE2D2-22-D-0142) represents an active federal award notice issued by DLA Troop Support, a key office within the Department of Defense responsible for providing logistical support to military and federal agencies. The contract is focused on the procurement of Febuxostat, a pharmaceutical product classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505, which pertains to drugs and biologicals.
The scope of this national contract encompasses the supply of Febuxostat to meet the needs of federal entities, with the place of performance designated as Columbus, Ohio, United States. The intent is to ensure a reliable and consistent source of this medication, supporting the health and readiness of personnel served by DLA Troop Support. Contractors engaged in pharmaceutical manufacturing and distribution, particularly those with capabilities aligned to the production and supply of Febuxostat, may find this opportunity relevant to their expertise.
Key requirements for this contract include compliance with federal standards for pharmaceutical manufacturing, as well as the ability to deliver products to the specified location in Columbus, Ohio. The contract is managed by DLA Troop Support, and interested parties or current awardees can direct inquiries to the primary contact, Keith Ryales ([email protected]), or the secondary contact, Jason Wray ([email protected]).
The notice is currently active and was posted on April 4, 2025. It is accessible via the official SAM.gov portal (Opportunity ID: a508ddee89b542ebbd2dbd8bbea19b70), where additional attachments related to the contract may be reviewed. While specific set-aside requirements and special considerations are not detailed in the provided information, contractors should refer to the official notice and its attachments for further guidance on eligibility and compliance.
Overall, this contract represents a significant opportunity for qualified pharmaceutical manufacturers to support federal healthcare initiatives through the supply of Febuxostat, with a focus on maintaining high standards of quality, reliability, and regulatory compliance throughout the contract lifecycle.
Documents6